Market research
FBRX Forte Biosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 73.8
- Dividend yield
- Not available
- Beta
- 2.65
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US34962G2084
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 73.8
- Dividend yield
- Not available
- Beta
- 2.65
About
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FBRX discussion.
5 years, 4 months ago
Forte Biosciences, Inc is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Forte Biosciences, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 56.8% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 65.9% to $-4M since the same quarter in the previous year.
Based on the above factors, Forte Biosciences, Inc gets an overall score of 3/5.